KPD

KPD
R-41 · CC BY-SA 3.0 · source
Name	KPD
Specialty	Endocrinology
Symptoms	Hyperglycemia, ketosis, polyuria, polydipsia
Onset	Adolescent to adult
Causes	Autoimmune markers variable; metabolic stressors
Risks	Obesity, family history, ethnic background
Diagnosis	Blood glucose, ketones, autoantibodies, C-peptide
Treatment	Insulin therapy, oral hypoglycemics, lifestyle modification
Prognosis	Variable; may achieve insulin independence

KPD is a clinical syndrome characterized by acute hyperglycemia with ketosis in patients who do not fit classical descriptions of established insulin-dependent or insulin-independent diabetes. It is encountered across diverse populations and intersects with findings familiar from studies of Type 1 diabetes mellitus, Type 2 diabetes mellitus, and autoimmune conditions such as those described in Graves disease or Hashimoto thyroiditis. KPD presents diagnostic and therapeutic challenges, drawing attention from investigators in fields linked to World Health Organization classifications, American Diabetes Association guidelines, and population cohorts like those from the Framingham Heart Study.

Definition and Nomenclature

KPD denotes a phenotype first delineated in observational series and registry analyses that contrasted with paradigms set by Joslin Diabetes Center case series and descriptions from early Diabetes Control and Complications Trial literature. Nomenclature in the literature varies, with labels influenced by classifications advanced by investigators associated with institutions such as National Institutes of Health and terminologies appearing in consensus statements from bodies like the International Diabetes Federation. Related constructs reference autoantibody status and beta-cell reserve, paralleling concepts used in studies from Harvard Medical School and Mayo Clinic.

Epidemiology and Demographics

Epidemiologic descriptions derive from cohorts in settings including United States, United Kingdom, Nigeria, India, and Mexico City. Prevalence estimates have been reported in cohort analyses from urban centers like New York City and research programs at University of California, San Francisco. Demographically, KPD is overrepresented among populations described in reports from African American communities, Hispanic and Latino Americans, and persons of Sub-Saharan Africa descent, with case series published by groups at Johns Hopkins University and University of Cambridge. Age distributions reported in multicenter registries span adolescents to middle-aged adults, echoing patterns seen in longitudinal research at Imperial College London.

Etiology and Pathophysiology

Etiologic models synthesize immunologic, genetic, and metabolic frameworks drawing on methodologies used in investigations from Broad Institute and genetic findings paralleling loci discussed in Genome-wide association study consortia. Some patients exhibit autoantibodies comparable to those characterized in Type 1 diabetes mellitus cohorts evaluated at Karolinska Institutet; others lack these markers but display insulin secretory defects measured by C-peptide assays applied in studies at Massachusetts General Hospital. Mechanisms implicate beta-cell dysfunction precipitated by metabolic stressors akin to those examined in Obesity research from Mount Sinai Health System and lipotoxicity pathways explored in laboratories at Salk Institute.

Clinical Presentation and Diagnosis

Clinically, presentation often mirrors acute metabolic decompensation encountered in emergency series described by American College of Emergency Physicians guidelines: polyuria, polydipsia, weight loss, and biochemical ketosis. Diagnostic workup follows algorithms similar to those promulgated by American Diabetes Association and includes plasma glucose, serum ketone measurement, arterial blood gas, and assays for autoantibodies used in protocols from Addenbrooke's Hospital. Differentiation uses C-peptide testing and longitudinal follow-up informed by practices at Cleveland Clinic and serologic testing paradigms developed at Pasteur Institute.

Treatment and Management

Initial management follows insulin-based resuscitation protocols analogous to those in Diabetic ketoacidosis guidelines from British Society for Paediatric Endocrinology and Diabetes and inpatient pathways used at St Thomas' Hospital. After resolution, a proportion of patients transition to regimens incorporating agents featured in randomized trials by UK Prospective Diabetes Study investigators, such as metformin or sulfonylureas evaluated in multicenter trials at Eli Lilly and Company and Novo Nordisk. Long-term strategies draw on multidisciplinary models implemented at centers like Mayo Clinic and community programs modeled on Centers for Disease Control and Prevention initiatives.

Prognosis and Complications

Outcomes are heterogeneous: several longitudinal cohorts from University of Miami and University of Texas Southwestern Medical Center report sustained insulin independence in subsets, whereas others evolve to require lifelong insulin reminiscent of courses seen in classical Type 1 diabetes mellitus registries at Barbara Davis Center for Childhood Diabetes. Complications mirror microvascular and macrovascular sequelae documented in trials such as DCCT and UKPDS and include retinopathy, nephropathy, and cardiovascular events tracked in population studies like Nurses' Health Study.

Research and Controversies

Active research programs at institutions including Stanford University, Columbia University, and University of Oxford probe genetic architecture, immunophenotypes, and metabolic triggers using resources from consortia like Human Genome Project derivatives and biobanks exemplified by UK Biobank. Controversies persist about classification—whether to subsume KPD within existing Type 1 diabetes mellitus or Type 2 diabetes mellitus frameworks—and about best predictors of remission, debated in editorials appearing in journals published by The Lancet and New England Journal of Medicine. Ongoing randomized trials and cohort studies coordinated through networks affiliated with National Institutes of Health aim to resolve therapeutic algorithms and prognostic biomarkers.

Category:Endocrinology